These collective findings form the foundation for our hypothesis that nucleoside-modified allergen-specific mRNA-LNP vaccines, by shaping CD4+ and CD8+ T cell responses and inducing allergen-specific IgG1 and IgG2 antibodies, could block Th2 cell activation and create an anti-allergic environment, thereby preventing manifestations of allergy including experimental asthma. This evidence concerns the gene CD8A and allergic disease.